Individuals with opioid use disorder (OUD) pass through jails each year, placing correctional facilities at the epicenter of the opioid crisis. Few jails offer the FDA-approved medications — buprenorphine, methadone, and naltrexone — that have consistently been shown to be the most effective forms of treatment for OUD when combined with behavioral therapies.
The Building Bridges demonstration project, co-funded by the Bureau of Justice Assistance and Arnold Ventures, supports a nine-month planning process for 16 counties committed to implementing medication-assisted treatment in jails and enhancing collaboration between jails and community-based treatment providers. Communities receive coaching and technical assistance to develop a comprehensive continuum of care model that targets the jail population and builds bridges between in-custody and community-based treatment and supervision, including probation, parole, and court-based programs.
Reducing overdose deaths and recidivism by establishing effective, comprehensive in-custody treatment and maintaining continuity of services from jail to community-based supervision.
The 16 communities participating in the Building Bridges Initiative came together August 13-14 in Arlington, Va., to hear from experts, learn from one another, and develop action plans to guide their work to provide OUD treatment in jails and develop a comprehensive continuum of care from jails to communities.
This webinar presentation by BJA includes a discussion of the types of questions Building Bridges Between Jail and Community-Based Treatment for Opioid Use Disorder communities may want to answer about their projects as well as the performance measures that will be required for sites that may wish to pursue BJA funding, if available in the future. The discussion also includes identification of specific data elements from across the justice and health sectors that sites should consider collecting.View the Webinar
The Substance Abuse and Mental Health Services Administration’s GAINS Center recently developed a brief on addressing medication diversion, particularly for MAT agonist medications, in correctional settings.View Resource >